@article{3121707,
    title = "Improvement of metabolic control after 3-month use of real-time continuous glucose monitoring in patients with type 1 diabetes: a multicenter study in Greece",
    author = "Eleftheriadou, I. and Didangelos, T. and Pappas, A.C. and Anastasiou, E. and Vasilopoulos, C. and Zoupas, C. and Manes, C. and Tsatsoulis, A. and Benroubi, M. and Pangalos, E. and Thomakos, P. and Gerasimidi-Vazeou, A. and Tentolouris, N.",
    journal = "Vitamins and Hormones",
    year = "2019",
    volume = "18",
    number = "4",
    pages = "443-450",
    publisher = "Springer-Verlag",
    doi = "10.1007/s42000-019-00153-1",
    keywords = "hemoglobin A1c;  insulin;  antidiabetic agent;  glycosylated hemoglobin, adult;  area under the curve;  Article;  clinical article;  clinical assessment;  clinical effectiveness;  clinical evaluation;  disease duration;  disease severity;  female;  follow up;  glycemic control;  Greece;  hospitalization;  human;  hypoglycemia;  insulin dependent diabetes mellitus;  ketoacidosis;  male;  metabolic regulation;  multicenter study;  prospective study;  risk factor;  adolescent;  blood;  blood glucose monitoring;  clinical trial;  devices;  glucose blood level;  insulin dependent diabetes mellitus;  insulin infusion;  middle aged;  patient compliance;  postmarketing surveillance;  procedures;  young adult, Adolescent;  Adult;  Blood Glucose;  Blood Glucose Self-Monitoring;  Diabetes Mellitus, Type 1;  Female;  Glycated Hemoglobin A;  Humans;  Hypoglycemia;  Hypoglycemic Agents;  Insulin Infusion Systems;  Male;  Middle Aged;  Patient Compliance;  Product Surveillance, Postmarketing;  Young Adult",
    abstract = "Purpose: To assess the efficacy of a real-time continuous glucose monitoring (RT–CGM) system added to insulin pump therapy for 3 months, in sub-optimally controlled adults with type 1 diabetes mellitus (T1D). Methods: This was a prospective, multicenter, non-randomized, post-market release study. A total of 43 adult patients with T1D on insulin pump therapy and inadequate glycemic control (HbA1c > 7.0%) participated in the study. The primary endpoint was the change from baseline HbA1c levels. Secondary objectives were to evaluate the impact of the RT–CGM system on glucose variability, daily insulin requirements, and the frequency of hypoglycemic and ketoacidosis events. Results: At 3 months, the baseline HbA1c values decreased from 8.0 (7.6, 8.7) to 7.1 (6.7, 8.0) % (p < 0.001). Nineteen participants (44.2%) had a posttreatment HbA1c level ≤ 7%. Average total daily insulin requirements, as well as the average number of insulin boluses per day, increased significantly after the use of the RT–CGM system. The number of hypoglycemic events recorded did not differ between the first week and last week of RT–CGM usage, while no severe hypoglycemic episodes, ketoacidosis events, or hospitalizations related to diabetes occurred during the 3-month follow-up period. Conclusion: Addition of a RT–CGM system to insulin pump therapy for 3 months in inadequately controlled patients with T1D resulted in improved HbA1c levels, without increasing the risk of hypoglycemic events. © 2019, Hellenic Endocrine Society."
}